FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4320517962> ?p ?o ?g. }

• W4320517962 endingPage "367" @default.
• W4320517962 startingPage "352" @default.
• W4320517962 abstract "Immune checkpoint inhibitors (ICIs) have shown promising efficacy in treatment and clinical management of advanced gastric and gastroesophageal junction cancer. However, the inhibitors also cause immune-related adverse events (irAEs). The current systematic review and meta-analysis study aimed to investigate the incidence and nature of irAEs caused by ICIs.To investigate the incidence and nature of irAEs in advanced gastric and gastroesophageal junction cancer.This systematic review was registered with PROSPERO (Reg. number: CRD42020152291). Data included in this study were collected from patients diagnosed with advanced gastric cancer or gastroesophageal junction cancer and treated with ICIs. A systematic literature search was conducted using the PubMed, EMBASE, and Cochrane Library databases. Meta-analysis was carried out using the single sample rate method. Synthesis and analysis of the data was conducted using Stata/SE and Review Manager Software.The patients enrolled in the present study included 14 patients from 14 case reports, 326 patients from 6 case series, and 1249 patients from 8 clinical trials. It was found that the overall incidence of irAEs was 16% [95% confidence interval (CI): 11-20] for all grades and 3% (95%CI: 2-4) for the severe grade. It was evident that the incidence of irAEs varied with the type of inhibitor and organs. A comparative study of the anti-programmed cell death receptor-1 (PD-1) and anti-programmed death receptor-ligand 1 (PD-L1) treatments showed that the anti-PD-1 group had a higher overall incidence of irAEs (20%) as compared with that of the anti-PD-L1 group (13%). Results of this study showed that the endocrine system experienced the highest incidence of organ-specific irAEs (7.4%), including hypothyroidism, hyperthyroidism, thyroiditis, diabetes, and adrenal insufficiency, followed by gastroenterology (2.2%), pulmonology (1.8%), neurology (1.4%), dermatology (1.4%), hematology (0.8%), and hepatology (0.7%). In clinical trials, it was found that the incidence of death related to irAEs was 1% (95%CI: 0-2.0), whereby colitis and interstitial lung diseases were the leading causes of death.It was evident that the incidence and nature of irAEs are both organ- and inhibitor-specific. The anti-PD-1 group had the highest incidence of all irAEs grades including the severe grades of irAEs. Early identification and management of irAEs allows clinical oncologists to effectively consider the pros and cons and hence enables them to strike a balance." @default.
• W4320517962 created "2023-02-14" @default.
• W4320517962 creator A5042923724 @default.
• W4320517962 creator A5062311355 @default.
• W4320517962 creator A5075810919 @default.
• W4320517962 creator A5078402132 @default.
• W4320517962 creator A5088548633 @default.
• W4320517962 date "2023-02-15" @default.
• W4320517962 modified "2023-09-26" @default.
• W4320517962 title "Immune-related adverse events associated with immune checkpoint inhibitors for advanced gastric and gastroesophageal junction cancer: A meta-analysis" @default.
• W4320517962 cites W1914776013 @default.
• W4320517962 cites W1978157711 @default.
• W4320517962 cites W2098923148 @default.
• W4320517962 cites W2125435699 @default.
• W4320517962 cites W2129183432 @default.
• W4320517962 cites W2130822830 @default.
• W4320517962 cites W2161367133 @default.
• W4320517962 cites W2235955903 @default.
• W4320517962 cites W2332470030 @default.
• W4320517962 cites W2588681363 @default.
• W4320517962 cites W2615677334 @default.
• W4320517962 cites W2725487442 @default.
• W4320517962 cites W2771850922 @default.
• W4320517962 cites W2783137027 @default.
• W4320517962 cites W2793364080 @default.
• W4320517962 cites W2794577178 @default.
• W4320517962 cites W2806614796 @default.
• W4320517962 cites W2877328171 @default.
• W4320517962 cites W2883552436 @default.
• W4320517962 cites W2888599070 @default.
• W4320517962 cites W2891486030 @default.
• W4320517962 cites W2897311709 @default.
• W4320517962 cites W2902391954 @default.
• W4320517962 cites W2903486314 @default.
• W4320517962 cites W2915665014 @default.
• W4320517962 cites W2919913683 @default.
• W4320517962 cites W2921789273 @default.
• W4320517962 cites W2922240698 @default.
• W4320517962 cites W2971012182 @default.
• W4320517962 cites W2979284539 @default.
• W4320517962 cites W2988355941 @default.
• W4320517962 cites W2995695264 @default.
• W4320517962 cites W3022709048 @default.
• W4320517962 cites W3029542402 @default.
• W4320517962 cites W3034197601 @default.
• W4320517962 cites W3035979332 @default.
• W4320517962 cites W3080554206 @default.
• W4320517962 cites W3080997916 @default.
• W4320517962 cites W3093660586 @default.
• W4320517962 cites W3105903533 @default.
• W4320517962 cites W3106005610 @default.
• W4320517962 cites W3106019786 @default.
• W4320517962 cites W3109713521 @default.
• W4320517962 cites W3118646141 @default.
• W4320517962 cites W3121932583 @default.
• W4320517962 cites W3123952636 @default.
• W4320517962 cites W3128646645 @default.
• W4320517962 cites W3128782849 @default.
• W4320517962 cites W3139107608 @default.
• W4320517962 cites W3154956818 @default.
• W4320517962 cites W3155996546 @default.
• W4320517962 cites W3157531134 @default.
• W4320517962 cites W3175499281 @default.
• W4320517962 cites W3197648443 @default.
• W4320517962 cites W3204206370 @default.
• W4320517962 doi "https://doi.org/10.4251/wjgo.v15.i2.352" @default.
• W4320517962 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36908315" @default.
• W4320517962 hasPublicationYear "2023" @default.
• W4320517962 type Work @default.
• W4320517962 citedByCount "0" @default.
• W4320517962 crossrefType "journal-article" @default.
• W4320517962 hasAuthorship W4320517962A5042923724 @default.
• W4320517962 hasAuthorship W4320517962A5062311355 @default.
• W4320517962 hasAuthorship W4320517962A5075810919 @default.
• W4320517962 hasAuthorship W4320517962A5078402132 @default.
• W4320517962 hasAuthorship W4320517962A5088548633 @default.
• W4320517962 hasBestOaLocation W43205179621 @default.
• W4320517962 hasConcept C120665830 @default.
• W4320517962 hasConcept C121332964 @default.
• W4320517962 hasConcept C121608353 @default.
• W4320517962 hasConcept C126322002 @default.
• W4320517962 hasConcept C143998085 @default.
• W4320517962 hasConcept C197934379 @default.
• W4320517962 hasConcept C2776478404 @default.
• W4320517962 hasConcept C535046627 @default.
• W4320517962 hasConcept C61511704 @default.
• W4320517962 hasConcept C71924100 @default.
• W4320517962 hasConcept C95190672 @default.
• W4320517962 hasConceptScore W4320517962C120665830 @default.
• W4320517962 hasConceptScore W4320517962C121332964 @default.
• W4320517962 hasConceptScore W4320517962C121608353 @default.
• W4320517962 hasConceptScore W4320517962C126322002 @default.
• W4320517962 hasConceptScore W4320517962C143998085 @default.
• W4320517962 hasConceptScore W4320517962C197934379 @default.
• W4320517962 hasConceptScore W4320517962C2776478404 @default.
• W4320517962 hasConceptScore W4320517962C535046627 @default.
• W4320517962 hasConceptScore W4320517962C61511704 @default.
• W4320517962 hasConceptScore W4320517962C71924100 @default.

• next